We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

PIEZO1 Overexpression Drives Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia: A New Therapeutic Target

MedXY Editorial Team•Oct 6, 2025•Cardiology
Hereditary hemorrhagic telangiectasia

Highlight

1. PIEZO1, a mechanosensitive ion channel, is overexpressed in endothelial cells of type 2 hereditary hemorrhagic telangiectasia (HHT) lesions.
2. Genetic deletion and pharmacological inhibition of PIEZO1 reduce arteriovenous malformation (AVM) formation in Alk1 knockout mouse models.
3. PIEZO1 signaling modulates key downstream pathways including VEGFR2/AKT, ERK5-p62-KLF4, and endothelial nitric oxide synthase, attenuating hypoxia, inflammation, and endothelial proliferation.
4. Targeting PIEZO1 presents a promising therapeutic strategy for preventing AVMs in ALK1-related vascular diseases.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Engasertib Shows Promise for Reducing Epistaxis in HHT but Benefits Are Modest — Safety Profile Acceptable in Short TermA randomized, double-blind placebo-controlled proof-of-concept trial of engasertib (AKT inhibitor) in hereditary hemorrhagic telangiectasia showed modest reductions in epistaxis frequency and duration versus placebo and a tolerable safety pNov 27, 2025Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term SafetyIn a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversibleNov 27, 2025
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story